信立泰
NEO Building No. 6009, Tower B
37th Floor Shennan Road Futian District
Shenzhen 518040
China
86 755 8386 7888
https://www.salubris.com
版塊: Healthcare
行業: Medical Instruments & Supplies
全職員工: 3,517
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Jie Yan | GM & Director | 無 | 無 | 1972 |
| Ms. Yun Kong | CFO & Financial Manager | 無 | 無 | 1973 |
| Mr. Ping Chen | Deputy General Manager | 無 | 無 | 1970 |
| Mr. Jianfeng Yang | Secretary of the Board of Directors & Non Independent Director | 無 | 無 | 1975 |
| Ms. Song Ping Zhao | Deputy General Manager | 無 | 無 | 1970 |
| Dr. Xie Heng M.D., Ph.D. | Chief Medical Officer | 無 | 無 | 無 |
描述
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also provides interventional medical devices for therapy of cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiology, and cardiac rhythm management. In addition, the company develops Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets, which are in phase III clinical trial for treatment of hypertension; Enarodustat, a drug for renal anemia; SAL056 medicine used for treating osteoporosis; and Fotagliptin and SAL015 for diabetes which are under phase III clinical trial. Further, it develops Sacubitril Allisartan Calcium and SAL007 medicine for chronic heart failure; SAL003 medicine that is in phase I clinical trial to treat hypercholesterolemia; and SAL0114 for depressant indications. Additionally, the company's preclinical products are SAL023 for osteoporosis; SAL0112 to treat diabetes; and SAL008 for the treatment of tumors. Furthermore, it develops medical devices, such as intracranial segment of vertebral artery stent, which is under clinical trials for Neurology intervention; SaExtenVena cava filter and Microneedle perfusion absolute ethanol delivery system used for Peripheral vascular intervention; and LAMax LAAC Left Atrial Appendage Occluder that is in clinical trials used for Structural heart disease. The company was founded in 1998 and is headquartered in Shenzhen, China. Shenzhen Salubris Pharmaceuticals Co., Ltd. is an operating subsidiary of Salubris Pharmaceuticals Co., Ltd.
公司管治
截至 無 止，信立泰 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
